Details of the Drug Combinations

General Information of This Drug (ID: DMNKBEC)

Drug Name

Infigratinib DMNKBEC

Synonyms

BGJ398

Indication

Disease Entry	ICD 11	Status	REF
Cholangiocarcinoma	2C12.10	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

22 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
BGJ398 + Panobinostat	DCD4QPK	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
BGJ398 + Trametinib	DCK2VEK	Trametinib	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
BGJ398 + Trametinib	DCXWIX9	Trametinib	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
BGJ398 + Trametinib	DC0G6QD	Trametinib	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
BGJ398 + JQ1	DCJIVPA	JQ1	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
BGJ398 + JQ1	DCUFEZC	JQ1	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
BGJ398 + Ceritinib	DC84YGE	Ceritinib	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
BGJ398 + Ceritinib	DCKO5SS	Ceritinib	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
BGJ398 + Ceritinib	DCUR85F	Ceritinib	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
BGJ398 + GSK2126458	DCBMDSR	GSK2126458	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
BGJ398 + GSK2126458	DCXKGXA	GSK2126458	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
BGJ398 + GSK2126458	DCH0RAL	GSK2126458	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
BGJ398 + BMS-754807	DCIKFOR	BMS-754807	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
BGJ398 + BMS-754807	DCF0T5U	BMS-754807	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
BGJ398 + BMS-754807	DCCYTSA	BMS-754807	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
BGJ398 + MK-2206	DCYMFI4	MK-2206	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
BGJ398 + MK-2206	DCY8VM1	MK-2206	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
BGJ398 + MK-2206	DC2QISK	MK-2206	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
BGJ398 + SCH772984	DC5HG07	SCH772984	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
BGJ398 + SCH772984	DCFRLD9	SCH772984	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
BGJ398 + SCH772984	DCGIJAR	SCH772984	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
Everolimus + BGJ398	DCFH9OK	Everolimus	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 22 DrugCom(s)

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Alpelisib + BGJ398	DCBYJ7X	Alpelisib	Advanced Solid Tumors	[5]
------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 214622.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7877).
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
5	ClinicalTrials.gov (NCT01928459) Phase 1b Trial of BGJ398/BYL719 in Solid Tumors